Haemonetics Corporation (HAE) Stock Grade

About Haemonetics Corporation's fundamentals

Haemonetics is a $4.8 billion healthcare company with a P/E ratio of 26.2, indicating investors are paying a premium relative to current earnings. The company is experiencing revenue headwinds, having declined 2.0% year-over-year, though it maintains a net profit margin of 7.3%. Return on equity stands at 12.2%, reflecting moderate efficiency in generating profits from shareholder capital, and the company does not currently pay a dividend to shareholders.